Intensity Therapeutics, Inc. (INTS)
| Market Cap | 40.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.26M |
| Shares Out | 13.77M |
| EPS (ttm) | -1.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,272 |
| Open | 3.000 |
| Previous Close | 3.000 |
| Day's Range | 2.850 - 3.000 |
| 52-Week Range | 2.145 - 11.440 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 8.50 (+188.14%) |
| Earnings Date | Nov 13, 2024 |
About INTS
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for INTS stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 188.14% from the latest price.
News
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
SHELTON, Conn. , Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and deve...
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving I...
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn. , Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company")...
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
SHELTON, Conn. , Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Testing the efficacy and safety of Intensity's lead drug candidate, INT230-6, when combined with Standard-of-Care versus Standard-of-Care alone The endpoint is the change in pathological complete resp...
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel im...
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 r...
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy SHELTON, Conn. , July 9, 2024 /PRNewswire/ -- Intensit...
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
SHELTON, Conn. , May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug
Mid-2024, Intensity Therapeutics will start Phase 3 and Phase 2/3 trials respectively in soft tissue sarcoma and triple-negative breast cancer. INT230-6 has shown up to 95% tumor necrosis, prolonged ...
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
SHELTON, Conn. , May 10, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer Cash and investments of $10.5 million expected to fund operations through...
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
SHELTON, Conn. , April 2, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel i...
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer Year-end cash and investments of $14.8 million expected to fund operations through th...
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
SHELTON, Conn. , March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel ...
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
SHELTON, Conn. , Feb. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel i...
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
FDA provides "Study May Proceed" letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn. , Jan. 3, 2024 /PRN...
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn...
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection A single inject...
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
WESTPORT, Conn. , Dec. 1, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune...
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society ("CTOS"), demonstrating 93% disease control rate in patien...
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
The disease control rate for subjects in the monotherapy was 93% for patients who received at least one dose of INT230-6 INT230-6 extended survival in refractory soft tissue sarcoma subjects by nearly...
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
WESTPORT, Conn. , Sept. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and developm...
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WESTPORT, Conn. , Sept. 5, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immun...
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds Data Presented at ASCO Showed that Lead Asset INT230-6 Prolongs Survival Alone or in Combi...